Citicoline (CDP-choline) in the treatment of Parkinson's disease.

Marti Masso JF, Urtasun M.

Department of Neurosciences, 
Universidad del Pais Vasco, 
San Sebastian, Spain.

Clin Ther 1991 Mar-Apr;13(2):239-42

Abstract

The subjects were 20 patients with Parkinson's disease. They were aged 52 to 76 years and the duration of the disease ranged from four to 25 years (mean, 12.5 years).  All the patients were receiving levodopa alone or in combination with tricyclic antidepressants, amantadine, bromocriptine, anticholinergic agents, or lisuride. Each patient received 1,000 mg of CDP-choline intramuscularly daily for 15 days and then 500 mg daily for 15 days. After 30 days of treatment, the scores on the Columbia rating scale improved 7.3%; rigidity was improved 18.8%; times to walk 10 m and turn over were reduced 17.5% and 37.4%; and the handwriting test scores improved 19.7%. No side effects were reported.  Four patients with advanced Parkinsonian symptoms and psychotic side effects received 2,000 mg of CDP-choline subcutaneously or intravenously for seven days. No improvements in symptoms or treatment side effects were noted.

 | Home | Order |

 1.   CDP choline  may be useful in the treatment of Alzheimer's
 2.   CDP choline  therapeutic effects in Alzheimer's
 3.   CDP choline  choline  effects on cognition in patients with Alzheimer's
 4.   CDP choline  significant improvement in Alzheimer's after 1 month  
 5.   CDP choline  improved mental performance in Alzheimer's
 6.   CDP choline  improvement in glaucoma
 7.   CDP choline  therapeutic value in the treatment of glaucoma
 8.   CDP choline  improved retinal responses in patients with glaucoma
 9.   CDP choline  in acute ischemic stroke
10.  CDP choline  randomized trial in acute ischemic stroke
11.  CDP choline  treatment after traumatic brain injury
12.  CDP choline  action and effects in ischemic brain injury